These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37154583)

  • 21. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
    Papadimitriou M; Mountzios G; Papadimitriou CA
    Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors.
    Li J; Lan M; Peng J; Xiong Q; Xu Y; Yang Y; Zhou Y; Liu J; Zeng Z; Yang X; Zhang Z; Zhang P; Zhu Q; Wu W
    Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
    Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
    J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations.
    Mgoboza C; Okunlola FO; Akawa OB; Aljoundi A; Soliman MES
    Cell Biochem Biophys; 2022 Sep; 80(3):495-504. PubMed ID: 35588345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
    Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between the efficacy of talazoparib and the functional toll-like receptors 3 and 9 in triple negative breast cancer.
    Guney Eskiler G; Deveci Özkan A
    Mol Immunol; 2022 Jan; 141():280-286. PubMed ID: 34906906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
    Song W; Tang L; Xu Y; Xu J; Zhang W; Xie H; Wang S; Guan X
    Sci Rep; 2017 Feb; 7():42319. PubMed ID: 28176879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.
    Cañedo EC; Totten S; Ahn R; Savage P; MacNeil D; Hudson J; Autexier C; Deblois G; Park M; Witcher M; Ursini-Siegel J
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33470989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
    Chu YY; Yam C; Chen MK; Chan LC; Xiao M; Wei YK; Yamaguchi H; Lee PC; Han Y; Nie L; Sun X; Moulder SL; Hess KR; Wang B; Hsu JL; Hortobagyi GN; Litton J; Chang JT; Hung MC
    Am J Cancer Res; 2020; 10(2):648-661. PubMed ID: 32195033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
    Dawood S; Konstantinova M; Perazzo F; Kim SB; Villarreal-Garza C; Franco SX; Simon SD; El-Nahas T
    Chin Clin Oncol; 2020 Oct; 9(5):61. PubMed ID: 32819114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
    Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple negative breast cancer: new therapeutic approaches and BRCA status.
    Guney Eskiler G; Cecener G; Egeli U; Tunca B
    APMIS; 2018 May; 126(5):371-379. PubMed ID: 29696717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
    Guney Eskiler G; Ozman Z; Haciefendi A; Cansaran-Duman D
    Naunyn Schmiedebergs Arch Pharmacol; 2023 May; 396(5):1031-1041. PubMed ID: 36598514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells.
    Wu W; Zhao J; Xiao J; Wu W; Xie L; Xie X; Yang C; Yin D; Hu K
    Biochem Biophys Res Commun; 2021 Oct; 573():62-68. PubMed ID: 34388456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
    Tazzite A; Jouhadi H; Benider A; Nadifi S
    Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure based pharmacophore study to identify possible natural selective PARP-1 trapper as anti-cancer agent.
    Kumar C; P T V L; Arunachalam A
    Comput Biol Chem; 2019 Jun; 80():314-323. PubMed ID: 31078910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A drug design strategy based on molecular docking and molecular dynamics simulations applied to development of inhibitor against triple-negative breast cancer by Scutellarein derivatives.
    Akash S; Aovi FI; Azad MAK; Kumer A; Chakma U; Islam MR; Mukerjee N; Rahman MM; Bayıl I; Rashid S; Sharma R
    PLoS One; 2023; 18(10):e0283271. PubMed ID: 37824496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.